Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 0.83 |
| ▸ | POLB | P06746 | 3/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091117 | 0.93 | MAPT (0.86) | MAPTTP53POLB | |
| SCHEMBL13091035 | 0.92 | MAPT (0.85) | MAPTTP53POLBGAARXFP1 | |
| SCHEMBL13091153 | 0.92 | MAPT (1.00) | MAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL13091090 | 0.91 | MAPT (1.00) | MAPTTP53POLBRXFP1SMN1; SMN2 | |
| SCHEMBL13091082 | 0.91 | MAPT (1.00) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL13091104 | 0.91 | MAPT (0.90) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL13091034 | 0.91 | TP53 (1.00) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL13091022 | 0.89 | TP53 (0.89) | MAPTTP53POLBSMN1; SMN2THRB | |
| SCHEMBL13091084 | 0.89 | MAPT (1.00) | MAPTTP53POLBRXFP1SMN1; SMN2 | |
| SCHEMBL13091027 | 0.88 | MAPT (0.81) | MAPTTP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2009023558-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | BAX, BCL2, BAD | MAPT 2663/4885TP53 34/4885POLB 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.